Regulatory News:

Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.

The presentation will take place as follows:

  • Date: Wednesday, October 4th, 2017
  • Time: 4:00pm CEST
  • Venue: Wyss Center in Geneva, Switzerland

If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at anne.hennecke@mc-services.eu.

About PharnextPharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).For more information, visit www.pharnext.com

PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief Commercial Officercontact@pharnext.comorInvestor Relations (Europe)MC Services AGAnne Hennecke, +49 211 529252 22anne.hennecke@mc-services.euorInvestor Relations (U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1 212 362 1200matthew@sternir.comorFinancial Communication (France)ActifinStéphane Ruiz, +33 (0)1 56 88 11 15sruiz@actifin.frorMedia Relations (Europe)ALIZE RPCaroline CarmagnolMargaux Pronost+33 (0)1 44 54 36 64pharnext@alizerp.comorMedia Relations (U.S.)RooneyPartnersMarion Janic+1 212 223 4017mjanic@rooneyco.com

Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pharnext Charts.
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pharnext Charts.